ArticlePloS one2009
A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 139 citations in OpenAlex.
- Half-Space Proximal Networks (HSPNs): A Proxy for Multi-Query Similarity Searching Models Predicting Tumor-Homing Peptides.ACS omega · 2025Article
- Multi-Modal Imaging Probe for Glypican-3 Overexpressed in Orthotopic Hepatocellular Carcinoma.Journal of medicinal chemistry · 2021Article
- The impact of molecular tumor profiling on the design strategies for targeting myeloid leukemia and EGFR/CD44-positive solid tumors.Beilstein journal of nanotechnology · 2021Review
- Magnetic particle targeting for diagnosis and therapy of lung cancers.Journal of controlled release : official journal of the Controlled Release Society · 2020Review
- Liposome Drug Delivery System across Endothelial Plasma Membrane: Role of Distance between Endothelial Cells and Blood Flow Rate.Molecules (Basel, Switzerland) · 2020Review
- Phage display screening of therapeutic peptide for cancer targeting and therapy.Protein & cell · 2019Review
- Phage Display Libraries: From Binders to Targeted Drug Delivery and Human Therapeutics.Molecular biotechnology · 2019Review
- Novel Bi-Functional 14-mer Peptides with Both Ovarian Carcinoma Cells Targeting and Magnetic Fe₃O₄Nanoparticles Affinity.Materials (Basel, Switzerland) · 2019Article
- Non-small-cell lung cancer homing peptide-labeled dendrimers selectively transfect lung cancer cells.Immunotherapy · 2018Article
- Ultrasound Doppler as an Imaging Modality for Selection of Murine 4T1 Breast Tumors for Combination Radiofrequency Hyperthermia and Chemotherapy.Translational oncology · 2018Article
- Targeted Delivery of Cell Penetrating Peptide Virus-like Nanoparticles to Skin Cancer Cells.Scientific reports · 2018Article
- A set of cancer stem cell homing peptides associating with the glycan moieties of glycosphingolipids.Oncotarget · 2018Article
- Optimizing non-invasive radiofrequency hyperthermia treatment for improving drug delivery in 4T1 mouse breast cancer model.Scientific reports · 2017Article
- Lung Cancer-Targeting Peptides with Multi-subtype Indication for Combinational Drug Delivery and Molecular Imaging.Theranostics · 2017Article
- Antibody Engineering for Pursuing a Healthier Future.Frontiers in microbiology · 2017Review
- Inter-molecular β-sheet structure facilitates lung-targeting siRNA delivery.Scientific reports · 2016Article
- Advancement and applications of peptide phage display technology in biomedical science.Journal of biomedical science · 2016Article
- Tumor-Specific Peptide, Selected from a Phage Peptide Library, Enhances Antitumor Activity of Lactaptin.PloS one · 2016Article
- Targeting Tumors with Small Molecule Peptides.Current cancer drug targets · 2016Review
- In Vitro Selection of Cancer Cell-Specific Molecular Recognition Elements from Amino Acid Libraries.Journal of immunology research · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the leading cause of cancer-related mortality worldwide. The lack of tumor specificity remains a major drawback for effective chemotherapies and results in dose-limiting toxicities. However, a ligand-mediated drug delivery system should be able to render chemotherapy more specific to tumor cells and less toxic to normal tissues. In this study, we isolated a novel peptide ligand from a phage-displayed peptide library that bound to non-small cell lung cancer (NSCLC) cell lines. The targeting phage bound to several NSCLC cell lines but not to normal cells. Both the targeting phage and the synthetic peptide recognized the surgical specimens of NSCLC with a positive rate of 75% (27 of 36 specimens). In severe combined immunodeficiency (SCID) mice bearing NSCLC xenografts, the targeting phage specifically bound to tumor masses. The tumor homing ability of the targeting phage was inhibited by the cognate synthetic peptide, but not by a control or a WTY-mutated peptide. When the targeting peptide was coupled to liposomes carrying doxorubicin or vinorelbine, the therapeutic index of the chemotherapeutic agents and the survival rates of mice with human lung cancer xenografts markedly increased. Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin. The current study suggests that this tumor-specific peptide may be used to create chemotherapies specifically targeting tumor cells in the treatment of NSCLC and to design targeted gene transfer vectors or it may be used one in the diagnosis of this malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.